In Vitro Activity of Oxazolidinone against Nontuberculous Mycobacteria, Including Macrolide-Resistant Clinical Isolates. [PDF]
Antimicrob Agents Chemother, 2021 Kim DH, Kim SY, Koh WJ, Jhun BW.
europepmc +1 more source
The Struggle to End a Millennia-Long Pandemic: Novel Candidate and Repurposed Drugs for the Treatment of Tuberculosis. [PDF]
Drugs, 2022 Edwards BD, Field SK.
europepmc +1 more source
Characterization of In Vitro Resistance to Linezolid in Mycobacterium abscessus. [PDF]
Microbiol Spectr, 2023 Negatu DA, Aragaw WW, Dartois V, Dick T.
europepmc +1 more source
Tuberculosis in the European Region. [PDF]
Curr Trop Med Rep, 2023 Mencarini J +3 more
europepmc +1 more source
Linezolid in the era of bedaquiline-pretomanid-linezolid-based regimens: an indispensable challenge. [PDF]
Respir Res Clin PractSantos AP, Mello FCQ.
europepmc +1 more source
Current and emerging therapies for pulmonary tuberculosis in adults. [PDF]
BMJ MedMahmood A +5 more
europepmc +1 more source
New drugs for the management of tuberculosis. [PDF]
Curr Opin Infect DisCross GB.
europepmc +1 more source
Treatment-shortening regimens for tuberculosis: updates and future priorities. [PDF]
Breathe (Sheff), 2023 Saluzzo F +4 more
europepmc +1 more source
Side-by-Side Profiling of Oxazolidinones to Estimate the Therapeutic Window against Mycobacterial Infections. [PDF]
Antimicrob Agents Chemother, 2023 Negatu DA +4 more
europepmc +1 more source
Tuberculosis: So much accomplished and so much more to be done. [PDF]
Indian J Med ResGupta A.
europepmc +1 more source